Metoprolol

Metoprolol is a so-called cardioselective beta-blocker: it preferentially blocks the beta-1 adrenergic receptors, which are found mainly in the heart. By occupying these receptors, it prevents catecholamines, adrenaline and noradrenaline, from stimulating the heart muscle. The result is seen directly in how the heart works: the heart rate slows, the force of each contraction decreases and cardiac output, the amount of blood ejected per minute, falls. It is this relative resting of the heart that explains most of its therapeutic effects.

On blood pressure, the mechanism remains partly debated. The official label proposes three complementary pathways: antagonism of catecholamines at cardiac adrenergic sites, which lowers output, a central effect that reduces sympathetic nerve outflow to the periphery, and a decrease in the secretion of renin, an enzyme that governs blood pressure regulation. Metoprolol is then transformed in the liver, mainly by the enzyme CYP2D6. It undergoes a strong first-pass hepatic effect, which limits its oral bioavailability to about 50%. Its elimination half-life is short, 3 to 4 hours, but it can reach 7 to 9 hours in people who metabolize slowly via CYP2D6.

Metoprolol tartrate is indicated in three main situations. In arterial hypertension, it lowers blood pressure and reduces the accompanying cardiovascular risk. In angina, the pain that occurs when the heart lacks oxygen on exertion, it serves as maintenance treatment: by slowing the heart, it reduces the frequency of attacks and improves exercise tolerance. After a myocardial infarction, in patients whose circulatory condition is stable, it reduces cardiovascular mortality.

The two salts of metoprolol do not overlap exactly. Metoprolol succinate, an extended-release form, is used in compensated chronic heart failure, an indication where the weakened heart benefits from a gradual and steady slowing. Metoprolol tartrate, on the other hand, is not indicated in heart failure: it is used, for example, to control the heart rate in atrial fibrillation, a rhythm disorder. The prescribed salt therefore corresponds to a specific indication and a given dosing schedule.

The label recommends taking metoprolol tartrate tablets with meals or immediately afterward. The presence of food increases the amount of medicine actually absorbed, so taking the tablet always under the same conditions makes its effect more consistent from one day to the next. Regularity matters here as much as the dose: a beta-blocker works by keeping the heart at a stable pace, and skipping doses or shifting the timing makes this balance vary.

The most important point concerns stopping. You never stop metoprolol abruptly on your own initiative. The label reports that worsening of angina, and in some cases heart attacks, have occurred after an abrupt stop: the heart, used to being slowed, reacts to the sudden release of the brake. When a discontinuation is decided, the dose must be reduced in steps over one to two weeks, under medical supervision. If a bothersome effect appears, you talk to your doctor rather than stopping on your own.

The most frequent adverse effects follow directly from the slowing of the heart and the nervous system. According to the label, fatigue and dizziness affect about 10% of patients: these are the most common manifestations, often pronounced at the start of treatment. Shortness of breath and bradycardia, a heart rhythm that has become too slow, each concern about 3% of people. These signs are precisely those that monitoring seeks to detect, because they reflect the expected action of the medicine pushed one notch too far.

Other effects are reported at a frequency close to 5%. A depressed mood occurs in about 5 people out of 100, diarrhea in about 5%, and itching or a skin rash in about 5% as well. Most of these effects are not serious and resolve, but following them makes it possible to adjust the dose or consider an alternative if the discomfort persists. Discomfort that lasts or worsens should be reported to the doctor rather than allowed to settle in.

Metoprolol leaves two documented traces on the nutritional ground. The first concerns coenzyme Q10, a molecule essential to energy production in cells. A landmark study on bioenergetics showed that the clinically used adrenergic beta-blockers, including metoprolol, inhibit enzymes that depend on this coenzyme. The pharmacological effect is established, even if its concrete clinical translation remains debated. Food provides modest amounts of it, mainly through oily fish, such as salmon, sardines and mackerel, and through red meat. For the rest, the body makes most of its own coenzyme Q10.

The second trace concerns sleep. The nighttime production of melatonin, the hormone that prepares for falling asleep, goes through beta-1 adrenergic receptors in the pineal gland, the same ones that metoprolol blocks. Beta-blockers therefore reduce this secretion. In a randomized controlled trial conducted in hypertensive patients treated with a beta-blocker, melatonin supplementation improved sleep. In addition, magnesium, found in pumpkin seeds, spinach and dark chocolate, and vitamin B6 take part in ordinary nerve function. The plate covers these minerals and these good fats well, but it provides very little melatonin, a hormone the body makes itself and whose production the treatment slows. It is on this precise point that a targeted intake, in addition to the treatment and never in its place, makes sense.

Because metoprolol is metabolized by CYP2D6, anything that slows this enzyme raises its concentration in the blood, and therefore its effect. This is the case with certain antidepressants such as paroxetine or fluoxetine, with bupropion or with quinidine. Combining it with other medicines that slow the heart can in turn increase bradycardia. Telling your doctor and pharmacist about all your treatments makes it possible to anticipate these additions of effects. Two simple markers guide monitoring: the heart rate and blood pressure, whose bradycardia and hypotension are the frequent deviations to watch.

Two situations call for particular vigilance. In a person with diabetes, metoprolol can mask early signs of hypoglycemia, notably the acceleration of the heart, and it can promote severe and prolonged hypoglycemia. In a person with hyperthyroidism, it can mask certain signs of the disease, and an abrupt stop risks precipitating a thyrotoxic crisis. These cases reinforce the same rule: metoprolol is managed with your doctor, on figures followed over time, and never through a solitary decision.